Endometrial SUSD2+ mesenchymal stem/stromal cells in tissue engineering: Advances in novel cellular constructs for pelvic organ prolapse

David M.Z.B. Hennes; Anna Rosamilia; Jerome A. Werkmeister; Caroline E. Gargett; Shayanti Mukherjee

doi:10.3390/jpm11090840

Endometrial SUSD2⁺ mesenchymal stem/stromal cells in tissue engineering: Advances in novel cellular constructs for pelvic organ prolapse

David M.Z.B. Hennes
, Anna Rosamilia
, Jerome A. Werkmeister
, Caroline E. Gargett
, Shayanti Mukherjee

Obstetrics & Gynaecology Monash Health

Research output: Contribution to journal › Review Article › Research › peer-review

18 Citations (Scopus)

Abstract

Cellular therapy is an emerging field in clinical and personalised medicine. Many adult mesenchymal stem/progenitor cells (MSC) or pluripotent derivatives are being assessed simultaneously in preclinical trials for their potential treatment applications in chronic and degenerative human diseases. Endometrial mesenchymal stem/progenitor cells (eMSC) have been identified as clonogenic cells that exist in unique perivascular niches within the uterine endometrium. Compared with MSC isolated from other tissue sources, such as bone marrow and adipose tissue, eMSC can be extracted through less invasive methods of tissue sampling, and they exhibit improvements in potency, proliferative capacity, and control of culture-induced differentiation. In this review, we summarize the potential cell therapy and tissue engineering applications of eMSC in pelvic organ prolapse (POP), emphasising their ability to exert angiogenic and strong immunomodulatory responses that improve tissue integration of novel surgical constructs for POP and promote vaginal tissue healing.

Original language	English
Article number	840
Number of pages	21
Journal	Journal of Personalized Medicine
Volume	11
Issue number	9
DOIs	https://doi.org/10.3390/jpm11090840
Publication status	Published - Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Biomaterials
Bioscaffolds
Cell culture
Electrospinning
Endometrium
Menstrual blood
MSC
Nanofiber
Perivascular MSC
Tissue engineering

Access to Document

10.3390/jpm11090840Licence: CC BY

Cite this

@article{e0a9ed497bcc49f2b0637b90a7e40daa,

title = "Endometrial SUSD2+ mesenchymal stem/stromal cells in tissue engineering: Advances in novel cellular constructs for pelvic organ prolapse",

abstract = "Cellular therapy is an emerging field in clinical and personalised medicine. Many adult mesenchymal stem/progenitor cells (MSC) or pluripotent derivatives are being assessed simultaneously in preclinical trials for their potential treatment applications in chronic and degenerative human diseases. Endometrial mesenchymal stem/progenitor cells (eMSC) have been identified as clonogenic cells that exist in unique perivascular niches within the uterine endometrium. Compared with MSC isolated from other tissue sources, such as bone marrow and adipose tissue, eMSC can be extracted through less invasive methods of tissue sampling, and they exhibit improvements in potency, proliferative capacity, and control of culture-induced differentiation. In this review, we summarize the potential cell therapy and tissue engineering applications of eMSC in pelvic organ prolapse (POP), emphasising their ability to exert angiogenic and strong immunomodulatory responses that improve tissue integration of novel surgical constructs for POP and promote vaginal tissue healing.",

keywords = "Biomaterials, Bioscaffolds, Cell culture, Electrospinning, Endometrium, Menstrual blood, MSC, Nanofiber, Perivascular MSC, Tissue engineering",

author = "Hennes, \{David M.Z.B.\} and Anna Rosamilia and Werkmeister, \{Jerome A.\} and Gargett, \{Caroline E.\} and Shayanti Mukherjee",

note = "Funding Information: This research was funded by the National Health and Medical Research Council (NHMRC) of Australia: Grant 1159677 (C.E.G., S.M., J.A.W., and A.R.), Grant 1184841 (S.M., J.A.W. and A.R.) and 1173882 Investigator (C.E.G.); J\&J WiSTEM2 D Program; Hudson Institute of Medical Research; Monash University and the Victorian Government?s Operational Infrastructure Support Program. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = sep,

doi = "10.3390/jpm11090840",

language = "English",

volume = "11",

journal = "Journal of Personalized Medicine",

issn = "2075-4426",

publisher = "MDPI AG",

number = "9",

}

TY - JOUR

T1 - Endometrial SUSD2+ mesenchymal stem/stromal cells in tissue engineering

T2 - Advances in novel cellular constructs for pelvic organ prolapse

AU - Hennes, David M.Z.B.

AU - Rosamilia, Anna

AU - Werkmeister, Jerome A.

AU - Gargett, Caroline E.

AU - Mukherjee, Shayanti

N1 - Funding Information: This research was funded by the National Health and Medical Research Council (NHMRC) of Australia: Grant 1159677 (C.E.G., S.M., J.A.W., and A.R.), Grant 1184841 (S.M., J.A.W. and A.R.) and 1173882 Investigator (C.E.G.); J&J WiSTEM2 D Program; Hudson Institute of Medical Research; Monash University and the Victorian Government?s Operational Infrastructure Support Program. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/9

Y1 - 2021/9

N2 - Cellular therapy is an emerging field in clinical and personalised medicine. Many adult mesenchymal stem/progenitor cells (MSC) or pluripotent derivatives are being assessed simultaneously in preclinical trials for their potential treatment applications in chronic and degenerative human diseases. Endometrial mesenchymal stem/progenitor cells (eMSC) have been identified as clonogenic cells that exist in unique perivascular niches within the uterine endometrium. Compared with MSC isolated from other tissue sources, such as bone marrow and adipose tissue, eMSC can be extracted through less invasive methods of tissue sampling, and they exhibit improvements in potency, proliferative capacity, and control of culture-induced differentiation. In this review, we summarize the potential cell therapy and tissue engineering applications of eMSC in pelvic organ prolapse (POP), emphasising their ability to exert angiogenic and strong immunomodulatory responses that improve tissue integration of novel surgical constructs for POP and promote vaginal tissue healing.

AB - Cellular therapy is an emerging field in clinical and personalised medicine. Many adult mesenchymal stem/progenitor cells (MSC) or pluripotent derivatives are being assessed simultaneously in preclinical trials for their potential treatment applications in chronic and degenerative human diseases. Endometrial mesenchymal stem/progenitor cells (eMSC) have been identified as clonogenic cells that exist in unique perivascular niches within the uterine endometrium. Compared with MSC isolated from other tissue sources, such as bone marrow and adipose tissue, eMSC can be extracted through less invasive methods of tissue sampling, and they exhibit improvements in potency, proliferative capacity, and control of culture-induced differentiation. In this review, we summarize the potential cell therapy and tissue engineering applications of eMSC in pelvic organ prolapse (POP), emphasising their ability to exert angiogenic and strong immunomodulatory responses that improve tissue integration of novel surgical constructs for POP and promote vaginal tissue healing.

KW - Biomaterials

KW - Bioscaffolds

KW - Cell culture

KW - Electrospinning

KW - Endometrium

KW - Menstrual blood

KW - MSC

KW - Nanofiber

KW - Perivascular MSC

KW - Tissue engineering

UR - https://www.scopus.com/pages/publications/85114263320

U2 - 10.3390/jpm11090840

DO - 10.3390/jpm11090840

M3 - Review Article

C2 - 34575617

AN - SCOPUS:85114263320

SN - 2075-4426

VL - 11

JO - Journal of Personalized Medicine

JF - Journal of Personalized Medicine

IS - 9

M1 - 840

ER -

Endometrial SUSD2⁺ mesenchymal stem/stromal cells in tissue engineering: Advances in novel cellular constructs for pelvic organ prolapse

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Translating Endometrial Stem/Progenitor Cell Discoveries to Transform Women's and Girls' Gynaecological Health Outcomes

Advancing Women’s Urogynecological Health using Micro/Nanotechnologies

Cells and nanobiomaterials to treat and prevent Pelvic Organ Prolapse

Cite this

Endometrial SUSD2+ mesenchymal stem/stromal cells in tissue engineering: Advances in novel cellular constructs for pelvic organ prolapse

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Projects

Translating Endometrial Stem/Progenitor Cell Discoveries to Transform Women's and Girls' Gynaecological Health Outcomes

Advancing Women’s Urogynecological Health using Micro/Nanotechnologies

Cells and nanobiomaterials to treat and prevent Pelvic Organ Prolapse

Cite this

Endometrial SUSD2⁺ mesenchymal stem/stromal cells in tissue engineering: Advances in novel cellular constructs for pelvic organ prolapse